IDEAYA Biosciences Announces Participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 Corporate Guidance
2024-01-07
临床1期临床2期临床结果
SOUTH SAN FRANCISCO, Calif., Jan. 7, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 corporate guidance and program updates.
42nd Annual J.P. Morgan Healthcare Conference
Tuesday, January 9th, 2024 at 8:15 AM PT (11:15 AM ET)
Presentation by Yujiro S. Hata, Chief Executive Officer followed by analyst-hosted Q&A with Anupam Rama, Managing Director, US SMID Biotechnology Equity Research, J.P. Morgan
IDEAYA's 2024 corporate guidance and program updates include:
Balance sheet of $511.1 million of cash, cash equivalents and marketable securities as of September 30, 2023, and $134.7 million estimated net proceeds from subsequent follow-on financing and $10 million receivable from GSK, is anticipated to fund operations into 2028
International site activation and double-digit patient enrollment achieved in potential registration-enabling Phase 2/3 clinical trial of darovasertib and crizotinib combination in first-line HLA-A2(-) metastatic uveal melanoma (MUM)HLA-A2(-) metastatic uveal melanoma (MUM)
Clinical program update(s) in 2024 for potential registration-enabling Phase 2/3 clinical trial of darovasertib and crizotinib combination in first-line HLA-A2(-) MUM
Targeting clinical efficacy update from Phase 2 company sponsored neoadjuvant uveal melanoma (UM) study in mid-year 2024 and regulatory guidance update in 2024
Targeting ongoing enrollment of IDE397 and AMG 193 Phase 1 combination study in MTAP-deletion solid tumorsMTAP-deletion solid tumors and development of joint publication strategy in 2024
Anticipate First-Patient-In of Phase 1 IDE397 and Trodelvy® clinical combination study in MTAP-deletion bladder cancer in mid-year 2024
Preliminary IDE397 clinical efficacy observed in MTAP deletion solid tumorsMTAP deletion solid tumors, including RECIST 1.1 complete response in bladder cancer patient, 33% tumor shrinkage in NSCLC patient by CT/PET, and multiple ctDNA molecular responses in NSCLC and bladder cancer
Targeting IDE161 clinical program update(s) and enabling of clinical combination(s) in 2024
Preliminary IDE161 clinical efficacy observed in HRD solid tumors, including RECIST 1.1 partial responses in priority solid tumor types and >50% PSA reduction in a prostate cancer patient
Targeting ongoing enrollment of IDE161 Phase 1 expansion in HRD solid tumor priority types, including endometrial, colorectal, prostate, and ER+ HER2- breast cancersHER2- breast cancers
Advancing Phase 1 dose escalation for GSK101 (IDE705) Pol Theta Helicase inhibitor, and targeting IND submission in 2024 for Werner Helicase Inhibitor Development Candidate ($7.0 million milestone upon IND clearance) under collaboration with GSK
IDEAYA's updated corporate presentation reflecting its 2024 corporate guidance is available on its website, at the Investor Relations page: https://ir.ideayabio.com/.
A live audio webcast of the event, as permitted by conference host, will be available at the "Investors/News and Events/Investor Calendar" section of the IDEAYA website at https://ir.ideayabio.com/events. A replay of available webcasts will be accessible for 30 days following the live event.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to (i) participation in and/or presentation at certain investor relations events and (ii) 2024 corporate guidance. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's recent Quarterly Report on Form 10-Q filed on November 7, 2023 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.
Investor and Media Contact
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
[email protected]
SOURCE IDEAYA Biosciences, Inc.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
药物
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。